Market opened strong today with HSDT trading at $16.56, up 86% in pre-market trading as of this writing

Holy cow! If you weren’t watching Helius Medical Technologies (NASDAQ: HSDT) this morning, you missed one heck of a rocket ship! This little neurotech company is absolutely exploding higher—up a jaw-dropping 86% in pre-market trading as of this writing—and folks, this isn’t some meme stock nonsense. This is the real deal.

The Big News That’s Moving Markets

Helius just announced that their Portable Neuromodulation Stimulator (PoNS) stroke program hit a grand slam with the FDA. We’re talking about a “double-blind randomized clinical trial met the primary endpoint of demonstrating statistically significant greater improvements in gait and/or balance deficit due to stroke with active PoNS therapy”—that’s medical-speak for “it works, and it works really well.”

Now, here’s why this matters for your wallet and for millions of Americans. More than 7 million patients suffer from the symptoms of stroke and about 80% of them have balance and gait deficit. That’s a massive market, and Helius just proved their device can help these folks walk better and maintain their balance. The company is planning to file with the FDA in the third quarter under their breakthrough device designation.

What Exactly Is This PoNS Thing?

Think of it as a high-tech tongue stimulator that helps stroke patients regain their ability to walk and balance. The PoNS device, which delivers mild electrical impulses to the tongue, is indicated for use in the United States as a short-term treatment of gait deficit due to mild-to-moderate symptoms from MS and they’re now expanding into stroke treatment.

It sounds wild, but the science is solid. The device sends tiny electrical signals through your tongue to your brain, helping rewire the neural pathways that control movement and balance. Combined with physical therapy, patients are seeing real improvements in their quality of life.

The Numbers Game: Why Investors Are Going Crazy

Let’s talk turkey about what makes this stock move. A total of 159 patients were enrolled across the three studies, with 130 patients completing both the 12-week study treatment phase and the 12-week post treatment follow-up period. That’s a solid completion rate, and the results spoke volumes.

The company has been working on this for years, and they’re not some fly-by-night operation. Helius started the SRP in March 2024 after a positive interaction with the FDA on the data development program, study design, and endpoints. When the FDA gives you breakthrough designation—which they did back in 2021—they’re essentially fast-tracking your product because they believe it addresses an unmet medical need.

The Risk Side of the Equation

Now, let’s pump the brakes for a hot second. As much as I love a good biotech story, these stocks can be absolute heartbreakers. Here’s what keeps me up at night about HSDT:

FDA Risk: The PoNS has not yet been approved in the United States for use in stroke rehabilitation and remains investigational for this use. Until that rubber stamp comes from the FDA, this is all speculation. One regulatory hiccup and this stock could crater faster than a lead balloon.

Competition: The medical device space is brutal. Big pharma companies with deep pockets could swoop in with competing technologies or simply buy out smaller players like Helius.

Market Size Reality Check: While 7 million stroke patients sounds huge, the reality is that medical device adoption takes time. Insurance coverage, physician education, and patient acceptance all play roles in how quickly revenue ramps up.

What’s Already Working

Here’s what gives me confidence: PoNS has shown effectiveness in treating gait or balance and a significant reduction in the risk of falling in stroke patients in Canada, where it received authorization for sale in three indications. They’ve also got approvals in Australia, so this isn’t their first rodeo with regulators.

The company is already generating revenue from their multiple sclerosis indication in the US, which means they have commercial infrastructure in place. That’s huge because it shows they can actually sell these devices, not just develop them in a lab.

The Trading Perspective

As of this writing, HSDT was trading at $8.90 at Friday’s close and spiked to $16.56 in pre-market—that’s the kind of volatility that can make or break portfolios in a single session. If you’re thinking about jumping in, here’s my take:

The Bull Case: FDA approval could send this stock to the moon. With breakthrough designation and positive trial results, the regulatory path looks clearer than it has in years. The addressable market is enormous, and early adoption in other countries shows real commercial potential.

The Bear Case: Biotech stocks are notorious for giving back gains as fast as they make them. One negative FDA communication or trial delay could send shares tumbling. The company is still burning cash to fund these trials, and dilution is always a concern with smaller biotech names.

Bottom Line

Helius Medical is having its moment in the sun, and for good reason. They’ve got legitimate clinical data, regulatory momentum, and a massive market opportunity. But remember, this is biotech—it’s not for the faint of heart or anyone who can’t stomach 50% swings in either direction.

Whether you’re a seasoned trader or someone who’s just getting started in the markets, days like today remind us why staying informed about breaking news and market catalysts is so critical. The biggest moves often happen before most people even know what hit them.

This analysis is for educational purposes only and does not constitute investment advice. Always do your own research and consult with a qualified financial advisor before making investment decisions.

Want to stay ahead of market-moving news like this? Get real-time trade alerts and market insights sent directly to your phone. Tap here to join thousands of traders getting free daily stock alerts that could help you spot the next big move before it happens.